Safety indicators in the STRONG-HF trial from a methodological perspective

Acute heart failure (AHF) is associated with an increased risk of post-discharge clinical outcomes.1 In patients recently hospitalized for AHF, the Safety, Tolerability and Efficacy of Rapid Optimization, Helped by NT-proBNP Testing, of Heart Failure Therapies (STRONG-HF) trial showed that a high intensity care (HIC) strategy of rapid up-titration of guideline-directed medication (GDMT) and close follow-up reduce the risk of 180-day HF readmission or all-cause death, compared with usual care (UC).
Source: Journal of Cardiac Failure - Category: Cardiology Authors: Tags: Editorial Comment Source Type: research